Additionally, we found that ESCC patients with lymph node metastases frequently had higher ID3 and CD52 expressions than ESCC patients without lymph node metastasis (Fig. 4D). This evidence concerns the gene CD52 and metastatic malignant neoplasm in the lymph nodes.